首页|期刊导航|癌症生物学与医学（英文版）|DB-1310,a HER3-targeting antibody-drug conjugate,has synergistic anti-tumor activity with trastuzumab in HER2-and HER3-expressing breast cancer

DB-1310,a HER3-targeting antibody-drug conjugate,has synergistic anti-tumor activity with trastuzumab in HER2-and HER3-expressing breast cancer

Xi Li Liwen Liang Zhongyuan Zhu Haiqing Hua Yang Qiu

癌症生物学与医学（英文版）2025，Vol.22Issue(3)：231-236,6.

癌症生物学与医学（英文版）2025，Vol.22Issue(3)：231-236,6.DOI:10.20892/j.issn.2095-3941.2024.0586

DB-1310,a HER3-targeting antibody-drug conjugate,has synergistic anti-tumor activity with trastuzumab in HER2-and HER3-expressing breast cancer

Xi Li ¹Liwen Liang ¹Zhongyuan Zhu ¹Haiqing Hua ¹Yang Qiu¹

作者信息

1. Department of Research and Development,Duality Biologics,Ltd.,Shanghai 201204,China
折叠

摘要

引用本文复制引用

Xi Li,Liwen Liang,Zhongyuan Zhu,Haiqing Hua,Yang Qiu..DB-1310,a HER3-targeting antibody-drug conjugate,has synergistic anti-tumor activity with trastuzumab in HER2-and HER3-expressing breast cancer[J].癌症生物学与医学（英文版）,2025,22(3):231-236,6.

基金项目

This study was fully supported by Duality Biologics,Ltd. （）

癌症生物学与医学（英文版）

ISSN：2095-3941

访问量0

下载量0

段落导航